{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T09:10:21Z","timestamp":1791537021254,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40273-025-01529-5","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T18:27:58Z","timestamp":1754591278000},"page":"1293-1307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the Role and Policy Implications of Using External Evidence in Survival Extrapolations: A Case Study of Axicabtagene Ciloleucel Therapy for Second-Line DLBCL"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6402-2358","authenticated-orcid":false,"given":"Sam","family":"Harper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0389-7912","authenticated-orcid":false,"given":"Daniela","family":"Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4948-8831","authenticated-orcid":false,"given":"Brett","family":"Doble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8704-5022","authenticated-orcid":false,"given":"Oskar","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9138-8471","authenticated-orcid":false,"given":"Sachin","family":"Vadgama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0017-4863","authenticated-orcid":false,"given":"Julia Thornton","family":"Snider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7268-2560","authenticated-orcid":false,"given":"Stephen","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3374-9598","authenticated-orcid":false,"given":"Matthew","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"issue":"3","key":"1529_CR1","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jval.2024.11.013","volume":"28","author":"CL Gibbons","year":"2025","unstructured":"Gibbons CL, Latimer NR. Prevalence of immature survival data for anticancer drugs presented to the National Institute for Health and Care Excellence between 2018 and 2022. Value Health. 2025;28(3):406\u201314.","journal-title":"Value Health"},{"issue":"4","key":"1529_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jval.2020.10.016","volume":"24","author":"T-A Tai","year":"2021","unstructured":"Tai T-A, Latimer NR, Benedict \u00c1, Kiss Z, Nikolaou A. Prevalence of immature survival data for anti-cancer drugs presented to the National Institute for Health and Care Excellence and impact on decision making. Value Health. 2021;24(4):505\u201312.","journal-title":"Value Health"},{"issue":"3","key":"1529_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1017\/S0266462303000436","volume":"19","author":"U-G Gerdtham","year":"2003","unstructured":"Gerdtham U-G, Zethraeus N. Predicting survival in cost-effectiveness analyses based on clinical trials. Int J Technol Assess Health Care. 2003;19(3):507\u201312.","journal-title":"Int J Technol Assess Health Care"},{"issue":"6","key":"1529_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","volume":"33","author":"NR Latimer","year":"2013","unstructured":"Latimer NR. Survival analysis for economic evaluations alongside clinical trials: extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Mak. 2013;33(6):743\u201354.","journal-title":"Med Decis Mak"},{"issue":"6","key":"1529_CR5","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1377\/hlthaff.27.6.1642","volume":"27","author":"K Chalkidou","year":"2008","unstructured":"Chalkidou K, Lord J, Fischer A, Littlejohns P. Evidence-based decision making: when should we wait for more information? Health Aff (Millwood). 2008;27(6):1642\u201353.","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"1529_CR6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/13696998.2025.2506968","volume":"28","author":"A Petitjean","year":"2025","unstructured":"Petitjean A, Shang H, Bullement A, Latimer N. Use of external data to inform overall survival extrapolation in NICE technology appraisals for oncology drugs. J Med Econ. 2025;28(1):803\u201313.","journal-title":"J Med Econ"},{"issue":"3","key":"1529_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40487-023-00230-x","volume":"11","author":"S Palmer","year":"2023","unstructured":"Palmer S, Lin Y, Martin TG, Jagannath S, Jakubowiak A, Usmani SZ, et al. Extrapolation of survival data using a bayesian approach: a case study leveraging external data from Cilta-Cel therapy in multiple myeloma. Oncol Ther. 2023;11(3):313\u201326.","journal-title":"Oncol Ther"},{"issue":"20","key":"1529_CR8","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1002\/sim.8177","volume":"38","author":"T Bluhmki","year":"2019","unstructured":"Bluhmki T, Putter H, Allignol A, Beyersmann J, consortium CM. Bootstrapping complex time-to-event data without individual patient data, with a view toward time-dependent exposures. Stat Med. 2019;38(20):3747\u201363.","journal-title":"Stat Med"},{"issue":"4","key":"1529_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/0272989X16639900","volume":"37","author":"C Jackson","year":"2017","unstructured":"Jackson C, Stevens J, Ren S, Latimer N, Bojke L, Manca A, Sharples L. Extrapolating survival from randomized trials using external data: a review of methods. Med Decis Mak. 2017;37(4):377\u201390.","journal-title":"Med Decis Mak"},{"issue":"9","key":"1529_CR10","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jval.2019.03.017","volume":"22","author":"F Soikkeli","year":"2019","unstructured":"Soikkeli F, Hashim M, Ouwens M, Postma M, Heeg B. Extrapolating survival data using historical trial\u2013based a priori distributions. Value Health. 2019;22(9):1012\u20137.","journal-title":"Value Health"},{"issue":"1","key":"1529_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/pst.1589","volume":"13","author":"K Viele","year":"2014","unstructured":"Viele K, Berry S, Neuenschwander B, Amzal B, Chen F, Enas N, et al. Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat. 2014;13(1):41\u201354.","journal-title":"Pharm Stat"},{"issue":"5","key":"1529_CR12","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1177\/0272989X231168618","volume":"43","author":"A Bullement","year":"2023","unstructured":"Bullement A, Stevenson MD, Baio G, Shields GE, Latimer NR. A systematic review of methods to incorporate external evidence into trial-based survival extrapolations for health technology assessment. Med Decis Mak. 2023;43(5):610\u201320.","journal-title":"Med Decis Mak"},{"issue":"4","key":"1529_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1177\/0272989X11409240","volume":"31","author":"J Bilcke","year":"2011","unstructured":"Bilcke J, Beutels P, Brisson M, Jit M. Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide. Med Decis Mak. 2011;31(4):675\u201392.","journal-title":"Med Decis Mak"},{"issue":"4","key":"1529_CR14","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1467-985X.2008.00558.x","volume":"171","author":"N Welton","year":"2008","unstructured":"Welton N, Ades A, Caldwell D, Peters T. Research prioritization based on expected value of partial perfect information: a case-study on interventions to increase uptake of breast cancer screening. J R Stat Soc Ser A Stat Soc. 2008;171(4):807\u201341.","journal-title":"J R Stat Soc Ser A Stat Soc"},{"issue":"2","key":"1529_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cpt.2914","volume":"114","author":"O Sola-Morales","year":"2023","unstructured":"Sola-Morales O, Curtis LH, Heidt J, Walsh L, Casso D, Oliveria S, et al. Effectively leveraging RWD for external controls: a systematic literature review of regulatory and HTA decisions. Clin Pharmacol Ther. 2023;114(2):325\u201355.","journal-title":"Clin Pharmacol Ther"},{"key":"1529_CR16","unstructured":"MSAC. 1722: axicabtagene ciloleucel (Yescarta\u00ae) for relapsed or refractory large B-cell lymphoma. 2023. http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/1722-public. Accessed 15 Nov 2024."},{"key":"1529_CR17","unstructured":"MSAC. 1722.1: axicabtagene ciloleucel (Yescarta\u00ae) for relapsed or refractory large B-cell lymphoma. 2024. http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/1722.1-public. Accessed 15 Nov 2024."},{"key":"1529_CR18","doi-asserted-by":"crossref","unstructured":"CADTH. CADTH reimbursement review: axicabtagene ciloleucel (Yescarta). 2023. https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2023\/PG0293-Yescarta.pdf. Accessed 15 Nov 2024.","DOI":"10.51731\/cjht.2023.667"},{"key":"1529_CR19","unstructured":"DMC. Medicinr\u00e5dets anbefaling vedr\u00f8rende axicabtagene ciloleucel til andenlinjebehandling af patienter med DLBCL (The Danish Medicines Council's recommendation regarding axicabtagene ciloleucel for second-line treatment of patients with DLBCL). 2023. https:\/\/medicinraadet.dk\/media\/o5vpix0r\/medicinr%C3%A5dets-anbefaling-vedr-axicabtagene-ciloleucel-til-2-linjebeh-af-patienter-med-dlbcl-vers-1-0-x.pdf. Accessed 15 Nov 2024."},{"key":"1529_CR20","unstructured":"NICE. Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy [TA895]: Committee papers. 2022. https:\/\/www.nice.org.uk\/guidance\/ta895\/evidence. Accessed 15 Nov 2024."},{"key":"1529_CR21","unstructured":"HAS. Avis Economique: Yexcarta (axicabtageneciloleucel). 2023. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2023-11\/yescarta_29082023_avis_economique.pdf. Accessed 15 Nov 2024."},{"key":"1529_CR22","unstructured":"ZIN. Pakketadvies axicabtagene ciloleucel (Yescarta\u00ae) voor de behandeling van lymfeklierkanker (package advice axicabtagene ciloleucel (Yescarta\u00ae) for the treatment of lymphoma). 2024. https:\/\/english.zorginstituutnederland.nl\/binaries\/zinl-eng\/documenten\/reports\/2024\/06\/26\/package-advice-axicabtagene-ciloleucel-yescarta\/Package+advice+axicabtagene+ciloleucel+%28Yescarta%C2%AE%29+for+the+treatment+of+lymphoma.pdf. Accessed 15 Nov 2024."},{"key":"1529_CR23","unstructured":"NoMA. ID2022_020 Axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. 2023. https:\/\/www.nyemetoder.no\/4a2634\/siteassets\/documents\/rapporter\/id2022_020_axicabtagene-ciloleucel_yescarta_beh.-av-voksne-med-dlbcl-og-hgbl_subgruppe---hurtig-metodevurdering-kun-offentlig-versjon.pdf. Accessed 15 Nov 2024."},{"key":"1529_CR24","unstructured":"TLV. H\u00e4lsoekonomisk bed\u00f6mning av Yescarta (axicabtagenciloleucel). [Health economic assessment of Yescarta (axicabtagenciloleucel)]. 2023. https:\/\/www.tlv.se\/download\/18.5edcb30518c3e01e6562d14\/1701871508500\/bed231204_yescarta_3287-2022.pdf. Accessed 15 Nov 2024."},{"key":"1529_CR25","unstructured":"ClinicalTrials.gov. Study of effectiveness of axicabtagene ciloleucel compared to standard of care therapy in patients with relapsed\/\u200brefractory diffuse large B cell lymphoma (ZUMA-7). 2024. https:\/\/clinicaltrials.gov\/study\/NCT03391466. Accessed 5 Aug 2025."},{"key":"1529_CR26","unstructured":"ClinicalTrials.gov. Study evaluating the safety and efficacy of KTE-C19 in adult participants with refractory aggressive non-Hodgkin lymphoma (ZUMA-1). 2024. https:\/\/clinicaltrials.gov\/study\/NCT02348216. Accessed 15 Nov 2024."},{"issue":"19","key":"1529_CR27","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood.2022018893","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141(19):2307\u201315. https:\/\/doi.org\/10.1182\/blood.2022018893.","journal-title":"Blood"},{"issue":"6","key":"1529_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"1529_CR29","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jval.2021.10.015","volume":"25","author":"S Vadgama","year":"2022","unstructured":"Vadgama S, Mann J, Bashir Z, Spooner C, Collins GP, Bullement A. Predicting survival for chimeric antigen receptor T-cell therapy: a validation of survival models using follow-up data from ZUMA-1. Value Health. 2022;25(6):1010\u20137.","journal-title":"Value Health"},{"key":"1529_CR30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40273-014-0219-x","volume":"33","author":"EC Wilson","year":"2015","unstructured":"Wilson EC. A practical guide to value of information analysis. Pharmacoeconomics. 2015;33:105\u201321.","journal-title":"Pharmacoeconomics"},{"key":"1529_CR31","unstructured":"Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV). How should we assess and pay? Health-economic assessments and payment models for precision medicines and ATMPs. 2021. https:\/\/www.tlv.se\/download\/18.2f080b7e182629be22dd4e3c\/1660743327830\/rapport_rupm_atmp_eng.pdf. Accessed 5 Aug 2025."},{"key":"1529_CR32","unstructured":"Lymphoma SNQRf. Swedish National Quality Register for Lymphoma: annual report. 2024. https:\/\/statistik.incanet.se\/Lymfom\/. Accessed 12 Sep 2024."},{"issue":"1","key":"1529_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev-statistics-040120-010730","volume":"9","author":"CH Jackson","year":"2022","unstructured":"Jackson CH, Baio G, Heath A, Strong M, Welton NJ, Wilson EC. Value of information analysis in models to inform health policy. Annu Rev Stat Appl. 2022;9(1):95\u2013118.","journal-title":"Annu Rev Stat Appl"},{"issue":"3","key":"1529_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/0272989X07312724","volume":"28","author":"Z Philips","year":"2008","unstructured":"Philips Z, Claxton K, Palmer S. The half-life of truth: what are appropriate time horizons for research decisions? Med Decis Mak. 2008;28(3):287\u201399.","journal-title":"Med Decis Mak"},{"issue":"7","key":"1529_CR35","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2116133.","journal-title":"N Engl J Med"},{"issue":"6","key":"1529_CR36","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s41669-023-00435-w","volume":"7","author":"EF Peterse","year":"2023","unstructured":"Peterse EF, Verburg-Baltussen EJ, Stewart A, Liu FF, Parker C, Treur M, et al. Retrospective comparison of survival projections for CAR T-cell therapies in large B-cell lymphoma. Pharmacoecon Open. 2023;7(6):941\u201350.","journal-title":"Pharmacoecon Open"},{"issue":"Suppl. 1","key":"1529_CR37","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1182\/blood-2023-188473","volume":"142","author":"G Fridberg","year":"2023","unstructured":"Fridberg G, Amit O, Shargian L, Beyar Katz O, Grisariu S, Perry C, et al. Second vs third line treatment with axicabtagene ciloleucel for large B cell lymphoma: a real-life national multicenter retrospective cohort study with propensity score matching. Blood. 2023;142(Suppl. 1):4886.","journal-title":"Blood"},{"issue":"12","key":"1529_CR38","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1200\/OP.22.00315","volume":"18","author":"J Mikhael","year":"2022","unstructured":"Mikhael J, Fowler J, Shah N. Chimeric antigen receptor T-cell therapies: barriers and solutions to access. JCO Oncol Pract. 2022;18(12):800\u20137.","journal-title":"JCO Oncol Pract"},{"key":"1529_CR39","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s40273-017-0562-9","volume":"35","author":"SE Grimm","year":"2017","unstructured":"Grimm SE, Strong M, Brennan A, Wailoo AJ. The HTA risk analysis chart: visualising the need for and potential value of managed entry agreements in health technology assessment. Pharmacoeconomics. 2017;35:1287\u201396.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1529_CR40","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s40273-023-01242-1","volume":"41","author":"TM Otten","year":"2023","unstructured":"Otten TM, Grimm SE, Ramaekers B, Joore MA. Comprehensive review of methods to assess uncertainty in health economic evaluations. Pharmacoeconomics. 2023;41(6):619\u201332.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"1529_CR41","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jval.2019.02.008","volume":"22","author":"F Alarid-Escudero","year":"2019","unstructured":"Alarid-Escudero F, Enns EA, Kuntz KM, Michaud TL, Jalal H. \u201cTime traveling is just too dangerous\u201d but some methods are worth revisiting: the advantages of expected loss curves over cost-effectiveness acceptability curves and frontier. Value Health. 2019;22(5):611\u20138.","journal-title":"Value Health"},{"issue":"8","key":"1529_CR42","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.jval.2021.03.013","volume":"24","author":"SE Grimm","year":"2021","unstructured":"Grimm SE, Pouwels X, Ramaekers BL, van Ravesteyn NT, Sankatsing VD, Grutters J, Joore MA. Implementation barriers to value of information analysis in health technology decision making: results from a process evaluation. Value Health. 2021;24(8):1126\u201336.","journal-title":"Value Health."},{"issue":"2","key":"1529_CR43","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1017\/rsm.2024.17","volume":"16","author":"GF Nikolaidis","year":"2025","unstructured":"Nikolaidis GF, Woods B, Palmer S, Bujkiewicz S, Soares MO. Methods for information-sharing in network meta-analysis: implications for inference and policy. Res Synth Methods. 2025;16(2):291\u2013307.","journal-title":"Res Synth Methods"},{"issue":"1","key":"1529_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/0272989X241295665","volume":"45","author":"J Singh","year":"2025","unstructured":"Singh J, Anwer S, Palmer S, Saramago P, Thomas A, Dias S, et al. Multi-indication evidence synthesis in oncology health technology assessment: meta-analysis methods and their application to a case study of bevacizumab. Med Decis Making. 2025;45(1):17\u201333.","journal-title":"Med Decis Making"},{"issue":"3","key":"1529_CR45","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10742-021-00264-6","volume":"22","author":"A Bullement","year":"2022","unstructured":"Bullement A, Kearns B. Incorporating external trial data to improve survival extrapolations: a pilot study of the COU-AA-301 trial. Health Serv Outcomes Res Methodol. 2022;22(3):317\u201331.","journal-title":"Health Serv Outcomes Res Methodol"},{"issue":"7","key":"1529_CR46","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.jval.2017.12.023","volume":"21","author":"M Pennington","year":"2018","unstructured":"Pennington M, Grieve R, Van der Meulen J, Hawkins N. Value of external data in the extrapolation of survival data: a study using the NJR data set. Value Health. 2018;21(7):822\u20139.","journal-title":"Value Health"},{"issue":"10","key":"1529_CR47","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s40273-024-01406-7","volume":"42","author":"NR Latimer","year":"2024","unstructured":"Latimer NR, Rutherford MJ. Mixture and non-mixture cure models for health technology assessment: what you need to know. Pharmacoeconomics. 2024;42(10):1073\u201390.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1529_CR48","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1177\/0272989X11406986","volume":"31","author":"CH Jackson","year":"2011","unstructured":"Jackson CH, Bojke L, Thompson SG, Claxton K, Sharples LD. A framework for addressing structural uncertainty in decision models. Med Decis Making. 2011;31(4):662\u201374.","journal-title":"Med Decis Making"},{"issue":"5","key":"1529_CR49","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1177\/0272989X211068019","volume":"42","author":"M Vervaart","year":"2022","unstructured":"Vervaart M, Strong M, Claxton KP, Welton NJ, Wisl\u00f8ff T, Aas E. An efficient method for computing expected value of sample information for survival data from an ongoing trial. Med Decis Mak. 2022;42(5):612\u201325.","journal-title":"Med Decis Mak"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01529-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01529-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01529-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:42:03Z","timestamp":1760715723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01529-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1529"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01529-5","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"27 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the supplementary material.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article was commissioned and funded by Kite, a Gilead Company. Kite, a Gilead Company, provided insight into the manuscript and the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Brett Doble, Sachin Vadgama and Julia Thornton Snider are employees of Kite, a Gilead Company. Oskar Eklund is an employee of Gilead Sciences Nordics. Stephen Palmer received personal fees from Kite, a Gilead Company during the conduct of the study. Sam Harper, Daniela Afonso, Karina Watts and Matthew Taylor are employees of YHEC, who received consultancy fees from Kite, a Gilead Company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are not openly available because of reasons of sensitivity and are available from the corresponding author upon reasonable request. Data are located in controlled access data storage at Kite, a Gilead Company.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SH, BD, SV, SP and MT were involved in the conceptualisation of the study. SH and DA collected data and undertook the qualitative analysis. SH, SP, BD, MT and OE collaborated to generate the quantitative analysis. All authors were involved in the interpretation of data and preparation of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}